ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
Volume 0.13M
Average 0.07M
Returns on capital
ProMIS Neurosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
3155.8%
avg 66635.3%
ROIC
3267.2%
avg -228592.4%
ROA
-432.6%
avg -13237.8%
Analysis
ROIC is currently the strongest return metric at 3267.2% versus its period average of -228592.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Neil K. Warma | Chief Executive Officer, President, Compliance Officer & Director | CAD 604K | 63 | 160.00K | 1.78% |
Johanne Kaplan | Chief Development Officer | CAD 519.67K | 66 | 6.22K | 0.07% |
Larry Douglas Altstiel | Chief Medical Officer | CAD 482K | 76 | 165.00K | 1.84% |
Eugene Williams | Co-Founder & Chairman | CAD 218.75K | 67 | 5.50K | 0.06% |
Daniel E. Geffken | Chief Financial Officer | CAD 86.38K | 69 | 2.50K | 0.03% |
Neil R. Cashman | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director | — | 74 | — | — |
Dennis Chen | Head of Manufacturing & Senior Consultant | — | — | — | — |
David Wishart | Chief Physics Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Sep 29, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$18.83M
Sells
0
$0.00
Net Transaction Value
+$18.83M
Net buying
Most Active
Williams Eugene
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 5, 26Aug 5, 2026 | Kaplan Johanne Direct | Buy | $30.3K$30,324.00 |
| Apr 22, 26Apr 22, 2026 | Kirwin Patrick D. Indirect | Buy | $45.3K$45,320.00 |
| Mar 5, 26Mar 5, 2026 | Williams Eugene Direct | Buy | $48.8K$48,800.00 |
| Mar 4, 26Mar 4, 2026 | Williams Eugene Direct | Buy | $48K$48,000.00 |
| Mar 3, 26Mar 3, 2026 | Williams Eugene Direct | Buy | $21.9K$21,890.00 |
| Mar 2, 26Mar 2, 2026 | Williams Eugene Direct | Buy | $22.5K$22,530.00 |
| Feb 19, 26Feb 19, 2026 | Kaplan Johanne Direct | Buy | $25K$25,005.15 |
| Feb 3, 26Feb 3, 2026 | ABG Management Ltd. Indirect | Buy | $8.5M$8,499,988.33 |
| Feb 3, 26Feb 3, 2026 | ABG Management Ltd. Indirect | Buy | $10.1M$10,090,670.40 |
Summary
Insiders reported 9 buys worth $18.83M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $18.83M. Williams Eugene was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does ProMIS Neurosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PMN's management, answered from reported figures.
Who manages PMN?
ProMIS Neurosciences, Inc. (PMN) lists 8 active executives. The top listed executive is Neil R. Cashman, Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director.
Are PMN insiders buying or selling?
Recent insider activity shows net buying of $60.73M.
Continue the stock analysis
Jump to another research area for this company.